Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
488 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06430346 | Exercise Prehabilitation for Locoregional Esophageal Cancer | recruiting | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06530615 | Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer | active not recruiting | — | 119 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 |
| clinicaltrials |
| NCT04464668 | Colorectal Cancer Awareness, Research and Education and Screening - Rural Expansion, Access and Capacity for Health(CARES-REACH) | active not recruiting | — | 49 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06947083 | Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | recruiting | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06519097 | Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) | active not recruiting | Phase 2 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | recruiting | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03426891 | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | completed | Early Phase 1 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05065944 | Comparing Pre-Anesthesia Evaluation Via Telemedicine Versus in Person for Surgical Patients at Moffitt Cancer Center | completed | — | 106 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03043599 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03575325 | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | completed | Phase 2 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06463184 | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT04101526 | Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance | completed | N/A | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 2 | Oct 29, 2024 | clinicaltrials |
| NCT02061423 | HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy(Neoadjuvant) | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04257474 | Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk(B-SUPER) | completed | — | 265 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT02313272 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT00101101 | Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | completed | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT03215810 | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT02157610 | Smoking Cessation for Cervical Cancer Survivors | completed | N/A | 202 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT01176474 | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | completed | Phase 1 | 73 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03927274 | Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma | terminated | Early Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT04914000 | Motivating a Spectrum of Cancer Patients to Quit Smoking | completed | N/A | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03906110 | Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) | completed | — | 327 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05048316 | Study to Develop a Group-Based E-Health Intervention for YA Cancer Survivors | completed | N/A | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05054218 | COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients | completed | — | 336 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04091165 | Mobile APP Utilization for Enhanced Post-Operative Nutritional Recovery | completed | — | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE | terminated | Early Phase 1 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03411031 | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | terminated | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT01253161 | Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT02803333 | Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study(ORIEN) | completed | — | 75 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT03137693 | Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | terminated | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT03663166 | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02973750 | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer | completed | — | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04980157 | CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers | completed | — | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02032810 | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03904199 | Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia | completed | Early Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT01657591 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT01859026 | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | completed | Phase 1 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02158234 | Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02572284 | Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02829931 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT01176461 | Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 | completed | Phase 1 | 127 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT01528046 | Metformin in Children With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03078361 | Latinos CARES (Colorectal Cancer Awareness, Research, Education and Screening) | completed | N/A | 159 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials